VistaGen Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by VistaGen Therapeutics, Inc. on September 25, 2019. The report addresses a specific regulatory event regarding the company's listing status on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a listing compliance event rather than financial performance.
Material Changes
The primary material change reported is the resolution of prior listing deficiencies. The Nasdaq Listing Qualifications Staff determined that the Company is now in full compliance with:
- The market value of listed securities standard (Nasdaq Listing Rule 5550(b)(2)).
- The minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)).
Compliance was achieved because the closing bid price of the Company's common stock was $1.00 per share or greater for the last 10 consecutive trading days.
Outlook and Management Commentary
Nasdaq has informed the Company in writing that the matter regarding the listing deficiencies is now closed. No additional guidance, risks, or contingencies were disclosed in this specific filing.
Investor Verification Points
- Confirm the current trading price of VTGN common stock to ensure it remains above the $1.00 minimum bid price threshold.
- Verify the company's continued compliance with Nasdaq Listing Rule 5550(b)(2) regarding the market value of listed securities.
- Review subsequent filings for any new notices from Nasdaq regarding listing standards.